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Abstract
Background: Joint damage remains a major complication associated with haemophilia and is widely accepted as
one of the most debilitating symptoms for persons with severe haemophilia. The aim of this study is to describe
how complications of haemophilia such as target joints influence health-related quality of life (HRQOL).
Methods: Data on hemophilia patients without inhibitors were drawn from the ‘Cost of Haemophilia across
Europe – a Socioeconomic Survey’ (CHESS) study, a cost-of-illness assessment in severe haemophilia A and B
across five European countries (France, Germany, Italy, Spain, and the UK). Physicians provided clinical and
sociodemographic information for 1285 adult patients, 551 of whom completed corresponding questionnaires,
including EQ-5D.
A generalised linear model was developed to investigate the relationship between EQ-5D index score and target
joint status (defined in the CHESS study as areas of chronic synovitis), adjusted for patient covariates including
socio-demographic characteristics and comorbidities.
Results: Five hundred and fifteen patients (42% of the sample) provided an EQ-5D response; a total of 692 target
joints were recorded across the sample. Mean EQ-5D index score for patients with no target joints was 0.875
(standard deviation [SD] 0.179); for patients with one or more target joints, mean index score was 0.731 (SD 0.
285). Compared to having no target joints, having one or more target joints was associated with lower index
scores (average marginal effect (AME) -0.120; SD 0.0262; p < 0.000).
Conclusions: This study found that the presence of chronic synovitis has a significant negative impact on HRQOL
for adults with severe haemophilia. Prevention, early diagnosis and treatment of target joints should be an
important consideration for clinicians and patients when managing haemophilia.
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Background
Haemophilia is a rare, lifelong bleeding disorder charac-
terised by a deficiency of coagulation factor, with an
estimated incidence of the two most common forms
(Haemophilia A, a Factor VIII deficiency; and Haemo-
philia B, a Factor IX deficiency) of 1 per 4000–5000 and
1 per 20,000, respectively [1, 2]. Approximately 70% of
cases arise via X-linked recessive inheritance; the
remaining 30% arise with no known familial history
(‘sporadic’ haemophilia) [3]. Its primary manifestation is
prolonged bleeding of the musculoskeletal system and,
less frequently, mucosal and cerebral haemorrhages;
persons with severe (coagulation factor < 1% of normal)
haemophilia are particularly prone to spontaneous bleed
events (occurring in the absence of notable trauma).
Approximately 80% of bleed events are intra-articular
in nature, two-thirds of which are reported in the knees,
elbows, and ankles [4]. Bleed events lead to swelling and
acute pain of the affected area, alleviated through infu-
sions of plasma-derived or recombinant coagulation
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factor and respite care [5]. Frequent bleed events (2–3 in
a six-month period) to the same joint site is associated
with chronic inflammation of the synovium and reduced
joint flexion and mobility, arising as a result of increased
volume of fluid within the joint [6]. In the absence of ap-
propriate management, chronic synovitis is a significant
risk factor for long-term deterioration of the joint via
haemophilic arthropathy, leading to chronic pain, joint
disfigurement, and disability [7–9].
With the advent of prophylactic factor concentrate
regimens, introduced in Europe in the 1980s, the majority
of persons with haemophilia (PWH) aged 30 and under
exhibit minimal joint damage relative to that of previous
generations [10]. However, risk of inhibitor development,
whereby an autoimmune response to factor concentrate
renders the product ineffective, is a significant risk for
PWH, particularly for newly diagnosed infants in the early
days of therapy exposure and those undergoing surgery
[11]. In the absence of effective treatment, either with by-
pass therapies or through ‘training’ the body to accept fac-
tor concentrate (‘immune tolerance induction’ or ITI), the
presence of an inhibitor can significantly increase bleed
frequency and accelerate joint damage [12].
The psychological burden of degenerative, heritable
diseases such as haemophilia is an important yet histor-
ically overlooked aspect of economic evaluations and
health policy considerations, which more often focus on
disease-related morbidity and mortality [13]. However,
as major therapeutic advances in haemophilia have ex-
tended life expectancy and improved clinical outcomes
for sufferers, more recent studies have shifted focus to
health-related quality of life (HRQOL) as an outcome
measure, either with generic or disease-specific instru-
ments [14, 15]. However, the specific impact of musculo-
skeletal complications of haemophilia has not so far
been considered in isolation.
The purpose of this paper is to utilise a recent (2015)
observational study in severe haemophilia across five
European countries to explore drivers of HRQOL. Spe-
cifically, the analysis will explore the relationship be-
tween target joints and HRQOL for severe PWH, and
the extent to which patient-reported health and well-
being is driven by long-term clinical outcomes. While
this topic has been explored to some detail within
single-country studies, the use of data from the ‘Cost of
Haemophilia in Europe – a Socioeconomic Survey’
(CHESS) dataset affords access to one of the largest
samples of patient-reported HRQOL of recent years.
Methods
Data source
CHESS is a retrospective, non-interventional study of se-
vere, inherited haemophilia A and B across five European
countries (France, Germany, Italy, Spain, and the UK).
The purpose of the study was to generate an annualised
economic burden of the condition through reporting of
12-month, haemophilia-related direct and indirect re-
source use [16]. One hundred and thirty-nine haematolo-
gists provided demographic and clinical information for
1285 adult (≥18 years) patients, 541 (42%) of whom com-
pleted a corresponding questionnaire covering out-of-
pocket medical expenditure, HRQOL (measured using the
EQ-5D-3 L) and work loss.
Study exclusion criteria was limited to patients diag-
nosed with an inhibitor at the time of study capture
(n = 52), due to a differing risk profile for bleeds and
Table 1 Patient characteristics (n = 515)
Age (mean ± SD) 37.7 ± 15.0
Age categories (%)
18–30 205 (39.8%)
31–40 119 (62.9%)
41–50 89 (17.3%)
51–60 50 (9.7%)
61 + 52 (10.1%)
Subtype (%)
Haemophilia A 400 (77.7%)
Haemophilia B 115 (22.3%)
Country (%)
France 180 (35.0%)
Germany 96 (18.6%)
Italy 118 (22.9%)
Spain 84 (16.3%)
UK 37 (7.2%)
Treatment Strategy (%)
On-demand 201 (39.0%)
Primary prophylaxis 314 (61.0%)
Physician-reported comorbidities
Depression 77 (15.0%)
Anxiety 84 (16.5%)
Target joints (total) 714
Target joints (mean ± SD (range)) 1.39 ± 1.44 (0–9)
Number of target joints (patient n, %)
Zero 157 (30.5%)
One 153 (29.7%)
Two 130 (25.2%)
Three or more 75 (14.6%)
Location of target joints (patient n, %)
Exclusively upper body 92 (25.7%)
Exclusively lower body 188 (52.5%)
Upper and lower body 78 (21.8%)
Note. Values are means ± SD or numbers (%)
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subsequent target joint development among these pa-
tients [12, 17].
EQ-5D
The EQ-5D is one of the most frequently used generic
tools for assessing HRQOL [18]. The questionnaire con-
sists of two sections, the first of which (health state)
consists of five dimensions (mobility, self-care, usual ac-
tivities, pain/discomfort, and anxiety/depression), with
responses rated on an ordinal (1–3) scale. For each of
the five dimensions, the respondent indicates the state-
ment best describing their ‘health state’ at that time, with
1 equivalent to ‘no issues’ and 3 to ‘severe issues’. A health
state index ‘utility’ score based on country-specific ‘value
sets’ is derived through an amalgam of the five responses,
with scores generally ranging from 0 (equivalent to ‘dead’)
to 1 (‘perfect health’), though scores of less than zero
(states ‘worse than dead’) can also be derived [19].
The second part of the EQ-5D is a visual analogue
scale (VAS). The respondent is asked to indicate how
good or bad their health is on that day, based on a scale
from 0 to 100, where zero represents ‘the worst health’
the respondent can imagine, and 100 ‘the best health
state’ the person can imagine. Corresponding country
population norms for both the EQ-5D index score and
the VAS were used in this analysis, with the exception of
Italy, for which the Spanish value set was used.
Target joint definition
A ‘target joint’ as defined in the CHESS study encom-
passes any joint with known chronic synovitis; in con-
trast to previous clinical studies [20], study investigators
were given discretion as to how this may be further de-
fined with respect to bleed frequency and period of ob-
servation. In order to explore the differential impact of
costs associated with lower and upper body joint
deterioration, target joints were categorised into two
groups based on their location. ‘Upper body’ target
joints were those in the shoulders, elbows, wrists, neck,
and spine; ‘lower body’ target joints consisted of hips,
knees, and ankles. The target joint variable was assessed
in three ways: as a binary 0/1 variable; as a binary 0/1 vari-
able split into upper and lower body joints; and as a
discrete variable.
Statistical analysis
Demographic data and EQ-5D index score and VAS re-
sponses were compared between the sample of patients
with no reported target joints and those with one or more
reported target joints. Means were used to describe con-
tinuous variables; categorical variables are described as
frequencies and proportions. Standard t-tests were con-
ducted in order to test for between-group differences.
The marginal effect of the presence of one or more
target joints on EQ-5D-3 L index score was assessed
using a generalized linear model (GLM). Health utility
data on a ‘poor’-‘good’ scale is often negatively skewed
with a large volume of unity values (i.e. perfect HRQOL)
and a long ‘tail’ from a select group of less healthy ‘out-
lier’ patients. The GLM is an extension of the linear re-
gression framework (Eq. 1) suitable for nonparametric
outcome variables [21, 22]. The GLM requires a link
function relating the conditional mean to the covariates,
and a distribution ‘family’ to specify the relationship be-
tween the variance and the mean [23]. The log-link func-
tion (Eq. 2) in combination with a Poisson distribution
(Eq. 3) is frequently used to model EQ-5D index scores
and was employed for this analysis [24]. Index scores were
transformed to a ‘disutility’ index score (nY = 1-Y) in order
to fit the model specification [25, 26]. A confirmatory ana-
lysis of the family and link functions was conducted using
the modified Park test [21, 22].
Fig. 1 Distribution of study cohort by count of target joints (N = 515)
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NDDCs12mth ¼ αþ β1 target jointsð Þ þ β2xi þ…þ βnxn
ð1Þ
Where i = 1, …, n
E yjx½  ¼ f x0βð Þ ¼ exp x0βð ÞIn E yjx½ ð Þ ¼ x0β ð2Þ
y  Var yjxð Þ ≈ E yjx½ ð Þλ ð3Þ
Additional model covariates were country of residence,
patient age, and physician-reported presence of mental
illness (anxiety and/or depression) via a stepwise inclu-
sion method. Results are presented as average mean ef-
fects (AME). All statistical analysis was conducted using
Stata 13 [27].
Results
Patient characteristics
The average age of the patient cohort was 37.7 years old,
with the majority of patients (62.9%) aged between 31
and 40 years (Table 1). Almost two-thirds (61.0%) of pa-
tients were receiving therapy via a prophylaxis regimen
at the time of the study.
A total of 714 target joints were recorded across the
study population (mean 1.39; SD 1.44; range 0–9) (Fig. 1).
Three hundred and fifty-eight patients (69.5%) were re-
ported diagnosed with one or more target joints, with the
majority (79%) diagnosed with one or two target joints.
The majority (52.5%) of patients had target joints exclu-
sively in the lower body.
Factors influencing HRQOL
The mean EQ-5D index score in the sample was 0.77
(SD 0.27) (Table 2). Age was found to have a negative
impact on HRQOL: index scores were found to decrease
as patients progressed into each 10-year age cohort. Pa-
tients from Germany had the highest index score (mean
0.90; SD 0.12) and the United Kingdom the lowest
Table 2 EQ-5D-3 L index score by target joint status
Total
(n = 515)
No target joints
(n = 157)
≥1 target joints
(n = 358)
Total 0.77 ± 0.27 0.87 ± 0.01 0.73 ± 0.29
Age categories
18–30 0.86 ± 0.01 0.94 ± 0.01 0.82 ± 0.21
31–40 0.78 ± 0.23 0.84 ± 0.16 0.74 ± 0.25
41–50 0.72 ± 0.28 0.86 ± 0.12 0.69 ± 0.30
51–60 0.67 ± 0.34 0.83 ± 0.19 0.63 ± 0.36
61 + 0.61 ± 0.36 0.73 ± 0.31 0.54 ± 0.36
Subtype
Haemophilia A 0.78 ± 0.26 0.87 ± 0.18 0.74 ± 0.28
Haemophilia B 0.76 ± 0.29 0.86 ± 0.18 0.70 ± 0.32
Country
France 0.75 ± 0.28 0.87 ± 0.18 0.69 ± 0.30
Germany 0.90 ± 0.12 0.93 ± 0.09 0.88 ± 0.13
Italy 0.85 ± 0.12 0.86 ± 0.14 0.84 ± 0.11
Spain 0.66 ± 0.34 0.71 ± 0.36 0.65 ± 0.33
UK 0.59 ± 0.36 0.78 ± 0.17 0.56 ± 0.38
Treatment strategy
On-demand 0.80 ± 0.26 0.87 ± 0.21 0.77 ± 0.27
Prophylaxis 0.75 ± 0.01 0.87 ± 0.01 0.71 ± 0.29
Physician reported comorbidities
Depression 0.60 ± 0.36 0.79 ± 0.33 0.55 ± 0.35
Anxiety 0.80 ± 0.26 0.87 ± 0.21 0.77 ± 0.27
Number of target joints (patient n, %)
One – – 0.76 ± 0.28
Two – – 0.76 ± 0.26
Three or more – – 0.62 ± 0.31
Location of target joints (patient n, %)
Exclusively upper body – – 0.77 ± 0.27
Exclusively lower body – – 0.73 ± 0.28
Upper and lower body – – 0.68 ± 0.31
Note: Values are means ± SD
Fig. 2 EQ-5D-3 L index score by number of target joints (N = 515)
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scores (mean 0.59, SD 0.37). Patients receiving prophy-
laxis had lower mean index scores compared to on-
demand (mean 0.80 versus 0.75).
Patients with no recorded target joints had signifi-
cantly higher utilities than those with one or more target
joints (mean 0.87 versus 0.73), with scores deteriorating
as the number of target joints increased (Fig. 2). Index
scores among patients with an upper body target joint
was broadly similar to those with a lower body target
joint (mean 0.77 versus 0.73). Patients with both an
upper and lower body target joint had lower index
scores versus those with target joints in one location
(upper or lower body) (mean index score 0.68, SD 0.31)
(Fig. 3).
Relationship between target joint status and EQ-5D VAS
Patients with no target joints reported the highest VAS
scores (mean 74.3, SD 0.9) (Table 3), while patients
with both an upper and lower body target joint re-
ported the lowest VAS scores (mean 64.4, SD 18.3).
VAS scores among patients with an upper body target
joint were identical to those with a lower body target
joint (mean 67.9). Mean reported VAS scores followed
a downward trend as the number of target joints in-
creased (Fig. 4).
Individual dimensions of the EQ-5D-3 L
Across all five dimensions of the EQ-5D-3 L, the major-
ity of patients reported no problems, with fewer than
one in ten patients reporting ‘extreme’ problems in any
dimension (Table 4). Across the cohort as a whole, as
well as within the cohort of patients with target joints,
pain/discomfort and anxiety/depression were the most
common dimensions in which ‘extreme’ problems were
reported. The cohort of patients with one or more target
joints consistently reported a higher frequency of ex-
treme problems compared to those with no target joints:
whether that be in mobility (0.0% versus 1.4%); self-care
(0.6% versus 2.0%); usual activities (0.6% versus 2.8%);
pain/discomfort (1.3% versus 4.7%); and anxiety/depres-
sion (3.2% versus 5.6%).
Multivariate analysis
The presence of one or more target joints was associated
with lower EQ-5D index scores (AME -0.120; SD 0.026;
p < 0.001) (Table 5). Patients in Germany or Italy with
one or more target joints had the highest index scores
(AME 0.110 and 0.121 respectively; p < 0.001); patients
in the UK were found to have the lowest mean index
scores (AME -0.154, SD 0.060). The AME of patient
age on index scores was minimal yet significant (mean
0.005; SD 0.001; p < 0.001). Anxiety/depression was
found to be associated with lower index scores (AME
-0.106; SD 0.001; p < 0.001).
Discussion and conclusion
The findings of this analysis suggest an association
between musculoskeletal complications of haemophilia
and HRQOL: patients with no recorded target joints
had the highest mean EQ-5D index and VAS scores;
further, the number of target joints was inversely
Fig. 3 EQ-5D-3 L index score by location of target joint
Table 3 EQ-5D VAS score by target joint status
Total 69.3 ± 17.0
Number of target joints (patient n, %)
Zero 74.3 ± 0.9
One 69.1 ± 15.7
Two 67.1 ± 17.5
Three or more 63.1 ± 16.5
Location of target joints (patient n, %)
Exclusively upper body 67.9 ± 15.0
Exclusively lower body 67.9 ± 16.7
Upper and lower body 64.4 ± 18.3
Note: Values are means ± SD
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correlated with both measures. There was limited differ-
ence in index scores for individuals with either an upper
or lower body target joint; patients with target joints in
both locations had the lowest HRQOL within both the
health state index score and VAS score. The results of the
multivariate analysis show that, despite the confounding
influences of age and nationality, the presence of one or
more target joints remained a significant driver of reduced
HRQOL among our study cohort.
The long-term complications of haemophilia can have
pronounced effects on HRQOL early in life – due to
anxiety over future problems – and later in life, when
the complications manifest themselves [28–30]. The
analysis supports previous studies which suggest haemo-
philia patients experience depression and anxiety more
often than the general population of a similar age [31].
Fatigue, loss of enjoyment, and reduced leisure pursuits
also seem to correlate positively with the presence of tar-
get joints [28–30]. The pain and discomfort dimension
of the EQ-5D-3 L was found to be particularly sensitive
to the presence of target joints, with more than eight
times as many patients reporting extreme pain or dis-
comfort when a target joint was recorded.
Fig. 4 EQ-5D VAS score by count of target joints
Table 4 Frequencies of item responses in each EQ-5D health
state dimension by target joint status (%)
Target joint status
Dimension All
(n = 515)
No target joints
(n = 157)
≥1 target joints
(n = 358)
Mobility
No problems 312 (60.6%) 114 (72.6%) 198 (55.3%)
Some 198 (38.4%) 43 (27.4%) 155 (43.3%)
Extreme 5 (1.0%) 0 (0.0%) 5 (1.4%)
Self-care
No problems 402 (78.1%) 135 (86%) 267 (74.6%)
Some 105 (20.4%) 21 (13.4%) 84 (23.5%)
Extreme 8 (1.6%) 1 (0.6%) 7 (2.0%)
Usual activities
No problems 343 (66.6%) 119 (75.8%) 224 (62.6%)
Some 161 (31.3%) 37 (23.6%) 124 (34.6%)
Extreme 11 (2.1%) 1 (0.6%) 10 (2.8%)
Pain/Discomfort
No problems 205 (39.8%) 95 (60.5%) 110 (30.7%)
Some 291 (56.5%) 60 (38.2%) 231 (64.5%)
Extreme 19 (3.7%) 2 (1.3%) 17 (4.7%)
Anxiety/Depression
No problems 308 (59.8%) 113 (72.0%) 195 (54.5%)
Some 182 (35.3%) 39 (24.8%) 143 (39.9%)
Extreme 25 (4.9%) 5 (3.2%) 20 (5.6%)
Table 5 Multivariate Poisson regression analyses of disutility
derived from EQ-5D index scores
Model 1 Model 2
Country
France Omitted
Germany -0.110a (0.025)
Italy -0.121a (0.022)
Spain 0.029a (0.034)
UK 0.154 (0.060)
Age 0.005b (0.001)
Mental illnessc 0.106b (0.001)
Has target joint 0.173a (0.031) 0.120a (0.026)
AIC 1.002 0.956
BIC − 3070.013 − 3068.135
Note: Results shown are average mean effect (AME) of each covariate on
EQ-5D ‘disutility’ (1 - index score). Standard errors are shown in brackets
aSignificant at the 95% level b Significant at the 99% level
cPhysician-reported anxiety or depression
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Our study has several limitations. The definition of a
target joint in this analysis differs from current European
guidelines that focus on bleed frequency as a measure of
target joint status [32]. While the definitions exhibit sig-
nificant overlap, reporting and observance of a bleed
event is more straightforward than obtaining a clinical
diagnosis of chronic synovitis, which often requires
ultrasound and/or MRI assessment [33]. As discussed
elsewhere [34], the definition of a target joint used in the
CHESS study encompasses both these standardized defi-
nitions based on bleed rates and a consideration for
longer-term degenerative changes to the joint tissue and
structure arising from repeat bleed events.
Further, while our analysis attempts to create a com-
prehensive model of the main factors influencing EQ-5D
index scores in severe haemophilia, there is the potential
that some drivers were not accounted for, such as BMI,
HIV/HCV seropositivity, and sociodemographic factors
such as employment and marital status [28, 30, 31, 35].
Our choice of HRQOL measure, though used widely,
also presents limitations with respect to sensitivity and
discriminatory power, particularly in comparison to the
more recent five-level (5 L) version [36].
Nevertheless, the results presented in this study suggest
that chronic synovitis in severe haemophilia is associated
with reduced HRQOL as measured by the EQ-5D. Ap-
proaches to minimising the long-term risk of joint damage
and deterioration among these patients – beginning at a
young age with proactive therapy protocols to minimise
bleed frequency and severity – will serve to reduce future
psychosocial burdens on patients and are a justification
for continued access to preventative therapy protocols.
Further studies should seek to combine the cost and
HRQOL consequences of bleed events and joint disease,
and hence to quantify the cost effectiveness of current
therapy protocols for severe haemophilia.
Our analysis demonstrates that haemophilia-related
medical complications, such as the presence of one or
more target joints, can have a major impact on HRQOL
for persons with severe haemophilia.
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